DiscGenics is pioneering the development of regenerative therapies aimed at alleviating chronic back pain caused by degenerative diseases of the spine. Central to their approach is the engineering of specialized therapeutic progenitor cells known as Discogenic Cells, which are derived from donated adult human intervertebral disc tissue. These cells are cultivated through a patented allogeneic cell culture manufacturing process, allowing for their enrichment and expansion in a controlled environment. DiscGenics' lead product candidate, IDCT (rebonuputemcel), is an injectable cell therapy designed to treat mild to moderate lumbar disc degeneration. This innovative treatment is administered non-surgically and has shown promising results in clinical studies, demonstrating significant improvements in pain, function, and quality of life for patients.

The IDCT therapy not only aims to relieve symptoms but also addresses the underlying causes of degenerative disc disease by potentially regenerating the disc tissue. Clinical trials have indicated that a single injection of IDCT can lead to increased disc volume and a reduction in the need for pain medications. The therapy has received designations from the U.S. Food and Drug Administration (FDA) as a regenerative medicine advanced therapy (RMAT) and Fast Track designation, highlighting its potential to transform the treatment landscape for patients suffering from chronic back pain. DiscGenics continues to advance its research and development efforts, with ongoing clinical evaluations to further establish the safety and efficacy of its regenerative cell-based therapies.

United States

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.

DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain.

DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

DiscGenics

Company Details